HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NXGL
NEXGEL, Inc.
There isn't enough reported data to score NXGL yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NXGL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
NXGL's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NXGL PE Valuation
NXGL has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NXGL Forward outlook
There aren't enough analyst estimates for NXGL to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NXGL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$14.20 | -$6.20 |
| Q1 2026 | -$8.00 | +$1.00 |
| Q4 2025 | -$7.60 | +$2.40 |
| Q3 2025 | -$7.40 | +$4.20 |
| Q2 2025 | -$8.00 | +$3.40 |
| Q1 2025 | -$9.00 | +$2.00 |
| Q4 2024 | -$10.00 | +$1.20 |
| Q3 2024 | -$11.60 | -$2.00 |
NXGL has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NXGL on profitability, with a higher operating margin.
NXGL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.7M | +28% |
| Q1 2026 | $2.7M | -5.6% |
| Q4 2025 | $2.8M | -8.1% |
| Q3 2025 | $2.9M | -0.2% |
| Q2 2025 | $2.9M | +100% |
| Q1 2025 | $2.8M | +122% |
| Q4 2024 | $3M | +181% |
| Q3 2024 | $2.9M | +141% |
NXGL's revenue has held roughly level: $4M last quarter, up 28% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -68% | -46 points |
| Q1 2026 | -36% | -8.5 points |
| Q4 2025 | -43% | -16 points |
| Q3 2025 | -25% | +2.1 points |
| Q2 2025 | -22% | +51 points |
| Q1 2025 | -28% | +41 points |
| Q4 2024 | -28% | +85 points |
| Q3 2024 | -27% | +23 points |
NXGL's operating margin was −68% last quarter, down 46 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
NXGL has the stronger cash trend. Its trailing FCF is up 0.1% versus its history, compared with HIMS at down 84%.
NXGL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $241K | +$1.2M |
| Q3 2025 | -$793K | +$436K |
| Q4 2024 | -$928K | -$256K |
| Q3 2024 | -$1.2M | -$148K |
| Q2 2024 | -$909K | +$473K |
| Q1 2024 | -$1.2M | -$447K |
| Q4 2023 | -$672K | -$15K |
| Q3 2023 | -$1.1M | -$176K |
NXGL has burned cash in almost every quarter: −$3M over the past year, against −$4M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NXGL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NXGL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.9% | +40.5K shares |
| 1 year | +18% | +67.9K shares |
| 3 years | +62% | +172K shares |
NXGL has 450,663 diluted shares, up 18% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NXGL Net Leverage
NXGL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NXGL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.8 | Neutral |
| Stochastic | 7.2 | Oversold |
NXGL's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NXGL PE vs Healthcare Sector
NXGL has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NXGL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.06 | 6.7% below |
| 20 week MA | $6.53 | 42% below |
| 50 week MA | $14.7 | 74% below |
| 100 week MA | $34.7 | 89% below |
| 200 week MA | $39.9 | 90% below |
NXGL is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over NXGL on returns for 2026, with the stronger performance.
NXGL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $62.4 | $62.4 | 0% |
| 2022 | $62.4 | $27.2 | -56% |
| 2023 | $27.2 | $42.6 | +57% |
| 2024 | $42.6 | $94.0 | +121% |
| 2025 | $94.0 | $30.6 | -67% |
| 2026 YTD | $30.6 | $3.79 | -88% |
NXGL's yearly returns have swung widely, from +121% in 2024 to −67% in 2025. It's down 88% so far in 2026.